Kura Oncology Inc. has announced the granting of nonstatutory stock options to seven new employees under its 2023 Inducement Option Plan. The awards, totaling options to purchase 122,250 shares of common stock, were approved by the company's Compensation Committee on October 1, 2025. Each option is priced at $9.20 per share, matching the closing price of Kura's stock on the grant date. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following three years, contingent on continued employment.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9539198-en) on October 03, 2025, and is solely responsible for the information contained therein.